Marijuana stocks have been out of the limelight for months now following the beating of the once praised cannabis companies. It was shock and disbelief for investors who lost huge sums of money from the sector-wide collapse.
Regaining investors’ interest, if ever, might take time. But if you were to assess the current situation, there’s one marijuana stock that bears watching. Among all, it seems that Aphria (TSX:APHA)(NYSE:APHA) has the best chance of surviving the carnage and delivering incredible gains.
Aphria was one of the cannabis producers that market analysts thought would make a big splash in 2019. From $8.15 at the start of the year, the stock rose by 74.35% to $14.21 in early February. The momentum was not sustained as price movements became erratic.
If you will recall, the company almost lost shareholder trust and confidence following claims it overpaid for assets acquired in Latin America. Aphria was able to prevent what could have been a massive stock sell-off.
A botched hostile takeover bid by Green Growth Brands and the resignation of a senior executive this year also affected the stock price. Fortunately, some good news was able to replace Aphria’s misfortunes.
After sinking further to $6.90 on August 1, Aphria was able to redeem its tainted image by reporting an industry-best 417% trailing-12-month revenue growth and a 158% quarter-over-quarter sales growth in Q4 fiscal 2019. The stock instantly jumped to $40.14% to $9.67 during the next trading session.
Finally, a major cannabis company was presenting a profitable quarter! The elation, however, did not last long. All the pot stocks were under pressure as the cannabis sector was becoming super volatile.
Back-to-back quarterly profits
The Leamington, Ontario-based pot producer reported an 849% increase in net revenue and $16.2 net income in the first quarter of fiscal 2020 compared with the same period in 2018. It was a second consecutive quarter of profitable growth.
Irwin Simon, Aphria’s interim CEO, partly attributes the company’s success to international business and the strength and growth of its brands, particularly Broken Coast. Simon believes the solid start in 2020 is a good sign that the company is on track to achieve its fiscal year financial outlook.
Aphria is not letting up as it continues to widen its production footprint. It is waiting for Health Canada to expedite the issuance of a licence for Aphria Diamond, its second cannabis greenhouse facility in Leamington.
Aphria One, Broken Coast, and Aphria Diamond can combine to produce an annualized production capacity of 255,000 kilograms. With such production capacity, the company can put up $650 million to $700 million of sales in the fiscal 2020.
As of this writing, the market cap has shrunk to $1.51 billion from $2.28 billion in August while the stock is down 23.7% year to date. But you can say the stock is selling at a bargain vis-à-vis the revenue targets in fiscal year 2020.
Market analysts are even forecasting a high of $26 in the next 12 months or a potential increase of 334% from $5.99. Aphria looks like the best cannabis play but sadly, not a strong buy. The cannabis sector is no longer the most exciting, but it is the riskiest.
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Christopher Liew has no position in any of the stocks mentioned.